JNJ stock news · Johnson & Johnson

Johnson & Johnson said its clinical trial for the Shockwave Javelin catheter had a 93.6% success rate.

Johnson & Johnson Reports Positive Clinical Outcomes for Impella Heart Pumps in HRPCI

Talks for Johnson & Johnson's orthopedics to merge with Smith & Nephew fall apart.

J&J's talks with Smith & Nephew ended, and the report says the deal could have changed the orthopedics market. It gives no clear change to J&J's outlook.

Talks for a merger between Smith & Nephew and Johnson & Johnson's orthopaedics division have fallen apart.

Johnson & Johnson's orthopaedics division will not join Smith & Nephew through these talks. The report gives no expected business effects, so it does not change Johnson & Johnson's outlook.

On Friday, nine out of eleven sectors went up, with cyclical sectors making the biggest gains.

Johnson & Johnson rose 1.33%, though health care shares had the smallest gain among advancing groups. The report gives no company news, so its business outlook is unchanged.

Today's Highlight: Could Johnson & Johnson's stock be at its lowest point?

Johnson & Johnson shares fell after its earnings report, and this article points to possible support near $246. It adds no new company results, so it does not change the company's outlook.

J&J is having its toughest day since April 2025 because its MedTech sales fell short.

Johnson & Johnson beat profit estimates and raised its full-year forecast, but MedTech sales missed and drug deals will cut 2027 profit. The news points in different directions.

Johnson & Johnson says new drug agreements will hurt their earnings in 2027.

Johnson & Johnson beat quarterly sales and adjusted-profit forecasts and raised its 2026 outlook, but falling adjusted profit and expected drug-deal costs leave the report mixed.

Cyclical industries did well in Tuesday's trading, while Health Care struggled behind.

Johnson & Johnson shares fell 5.40% as health care fell 1.07%. The report gives no new news about the company’s business, so its outlook is unchanged.

Johnson & Johnson shared details from their earnings call for the third quarter of 2026.

Johnson & Johnson reported 6% sales growth and raised its 2026 sales forecast. Medicine growth and the higher forecast outweigh slower MedTech sales and its challenges.

Companies will share their earnings on October 13, 2026.

Johnson & Johnson is expected to report quarterly results before the market opens. The article gives estimates, not actual results, so it does not change the outlook for the company.

Keep an eye on JPMorgan, Goldman Sachs, and 3 other stocks as Tuesday approaches.

Johnson & Johnson's expected profit and sales figures are forecasts, not reported results. The story gives no actual performance or company update, so it does not change the company's outlook.

JPMorgan Chase might see a $28 billion change after it shares its earnings.

Johnson & Johnson's estimates show lower earnings per share but higher sales than a year ago. With no results reported and no direction implied by the options estimate, the story does not change its outlook.

This week’s big news for the Dow Jones, S&P 500, and Nasdaq 100 is about the stock market.

Johnson & Johnson is named as a company due to report results, and the article gives a broad profit-growth estimate. Inflation and conflict could pressure stocks, but it reports no company-specific results or estimate.

This week’s big news for the Dow, S&P 500, and Nasdaq 100 is about the stock market.

Johnson & Johnson is named as a company due to report results. The story gives no company results or forecast to show how its business may change.

On Thursday, eight out of eleven sectors dropped, with Energy doing the best.

Johnson & Johnson shares fell 2.29% during the session. The article reports no company news, so this trading move alone does not change its business outlook.

On Monday, eight out of eleven sectors went up while the top performers were mixed.

Johnson & Johnson was listed at 0.83% as health care shares fell 0.15%. The story gives no new information about the company’s business.

Johnson & Johnson is getting ready to share its Q3 earnings, and analysts have changed their predictions.

JNJ is expected to report higher sales but lower profit for Q3. Positive therapy findings and analyst target increases add support, but the mixed signals leave its outlook unchanged.

Johnson & Johnson is expected to have steady sales but fall short on profits in its upcoming Q3 report.

Johnson & Johnson is expected to match sales estimates but fall short on profit. A higher sales estimate for Icotyde is a plus, but the profit miss weighs more.

On Monday, eight out of eleven sectors dropped, but defensive ones like Energy and Health Care did well.

Johnson & Johnson shares rose 0.39% as health care shares gained 0.11%. The report describes one trading session, not a change in the company’s business outlook.

On Thursday, eight out of eleven sectors dropped, while some leaders had mixed results.

Johnson & Johnson appears with a positive percent in Health Care names, which signals a positive trading move today.

Pete Buttigieg calls out corruption in U.S. politics, saying big companies are taking over elections and getting what they want.

Johnson & Johnson was grouped with 'Big Pharma' in the criticism. The piece offers no new regulation or company-specific claim, so it does not change J&J's outlook.

Who are the wealthiest NFL team owners and how are they linked to the stock market?

Johnson & Johnson is mentioned because the Johnson brothers, heirs to J&J, own the New York Jets; there is no healthcare or sales news for J&J.

Johnson & Johnson enhances its robotic bronchoscopy platform through an upgrade featuring AI and 3D navigation.

Johnson & Johnson's receipt of U.S. 510(k) regulatory clearance for its MONARCH QUEST 3 software marks a significant advancement in its robotic bronchoscopy platform. This upgrade, which includes AI-powered features and improved navigation, is expected to enhance clinical outcomes and could lead to increased adoption of the technology in medical facilities, positively impacting the company's…